tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael Ulz, 102 are a BUY (61.45%), 58 are a HOLD (34.94%), 6 are a SELL (3.61%).
Analyst Michael Ulz, currently employed at BAIRD, carries an average stock price target met ratio of 55.39% that have a potential upside of 42.9% achieved within 170 days.
Michael Ulz’s has documented 374 price targets and ratings displayed on 39 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SLN, Silence Therapeutics PLC at 09-May-2025.
Analyst best performing recommendations are on NRIX (NURIX THERAPEUTICS ).
The best stock recommendation documented was for CABA (CABALETTA BIO) at 8/30/2022. The price target of $3 was fulfilled within 76 days with a profit of $2.01 (203.03%) receiving and performance score of 26.71.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
4 years 1 months 12 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
4 years 1 months 14 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
4 years 1 months 22 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
4 years 4 months 13 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
4 years 5 months 10 days ago
(07-Jan-2021)
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Michael Ulz is most bullish on?
Which stock is Michael Ulz is most reserved on?
What Year was the first public recommendation made by Michael Ulz?
